Penn Medicine Abramson Cancer Center


 

2020 ASCO CRC Update: Encorafenib and Cetuximab in BRAF V600 mCRC, IO in MSI-high mCRC, DFS With TNT and Selective Waiting / TME vs. SoC

195 views
July 15, 2020
Comments 0
Login to view comments. Click here to Login